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ABSTRACT The folic acid antagonists, metho-
trexate and aminopterin, are known to be teratogenic in
humans. The critical period for their teratogenecity is
suspected to be between 6 to 8 weeks post-concep-
tion. Fetal exposure from 10 to 32 weeks weeks
post-conception to methotrexate alone or in combina-
tion with other anti-cancer drugs has not resulted in
obvious teratogenic effects. Methotrexate is often used
to treat cancers but is occasionally used as an abortifa-
cient. The long-term outcome of the fetal aminopterin
syndrome has been published in only four adults. We
report on a 28-year-old man with fetal methotrexate
syndrome and two children with mild manifestations of
the syndrome. One child was inadvertently exposed to
methotrexate from 71⁄2 through 30 weeks post-
conception because his mother was receiving it for
treatment of breast cancer. The other was exposed
from 11 weeks and 5 days through 25 weeks in an
attempt to induce abortion. The 28-year-old man has
craniofacial and digital anomalies, growth retardation
but normal intelligence as noted in the previously
reported cases. These cases remind us of the terato-
genicity of methotrexate and should serve as a warning
that if methotrexate is used as an abortifaciant and an
abortion does not ensue, there is a teratogenic risk.
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Aminopterin and its methyl derivative, methotrex-
ate, are folic acid antagonists used for the treatment of
various cancers, rheumatoid arthritis, psoriasis, and
occasionally as abortifaciants for the management of
ectopic or unwanted pregnancies. Prenatal exposure to
these drugs during critical periods of embryogenesis is
known to cause a multiple malformation syndrome in
humans. The critical gestation period has been sug-
gested to be from 6 through 8 weeks post-conception by
Feldkamp and Carey (’93) and by Donnenfeld et al.
(’94). The threshold dose for teratogenicity of methotrex-
ate is thought to be 10 mg per week. The long-term
outcome in fetal aminopterin syndrome has been pub-
lished in four adults. We report on a 28-year-old man
with fetal methotrexate syndrome and two children
with a partial form of the syndrome.
CASE 1
We examined CH at the age of 26 years for multiple
anomalies. His parents are African American with no
birth defects. His mother had five normal children after
him. She attempted to terminate this pregnancy by
taking an unknown quantity of methotrexate either 6
weeks post-conception or 6 weeks after the last men-
strual period. She gave him up for adoption soon after
birth. Some of the birth defects of his hands and feet
had been surgically corrected, but since his entire
medical record was available, a complete assessment
was possible. He has hypertelorism, (interpupillary
distance of 6.5 cm, 1 2.5 S.D.), ptosis of the eyelids,
short palpebral fissures (length 2.5 cm), sparse eye-
brows, prominent nose, low-set ears, and a widow’s
peak at the frontal hairline (Fig. 1). His height was 155
cm (23 S.D.), weight 39.7 kg (22.5 S.D.) and head
circumference was 51 cms (23.5 S.D.). He has addi-
tional flexion creases on the fingers (Fig. 2A). The ‘‘t’’
triradius is distally placed. A surgical repair of his
flexion contractures of the metacarpo-phalangeal joints
of both the thumbs and of syndactyly of all the fingers
was done at the age of 6 years. Figure 2B is a radio-
graph of his hands taken at the age of 6 years prior to
surgery.
He cannot fully extend his elbows due to subluxation
of the radial heads (Fig. 3). His great toes are broad. He
had surgical reconstruction of all the toes from a single
fused hypoplastic nub of tissue at the forefoot. He has
only four metacarpals and severe hypoplasia of phalan-
ges of the toes (see Fig. 4A, B). His genitalia are normal.
He developed gynecomastia at puberty for which he had
surgery. Radiographs also demonstrated defects in the
bones of the skull (Fig. 5). His early psychomotor
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development was normal and he passed 11th grade in a
regular classroom without any learning difficulties. He
is employed as a janitor in the family business. He has a
driver’s license. He seems well adjusted to his condi-
tion. His phenotype is compared to the published
reports of adults with this syndrome in Table 1.
CASE 2
Nine-year-old MP was born to a 45-year-old gravida 4
para 4 Caucasian woman at 29 weeks gestation weigh-
ing 820 g (small for gestation). His mother’s pregnancy
was undetected until she went into labor. About 4
weeks after her estimated date of conception (i.e., six
weeks after her last menstrual period) she had a
lumpectomy for breast cancer. She began chemother-
apy with methotrexate at 71⁄2 weeks post-conception.
Her chemotherapy schedule was as follows: 80 mg
methotrexate weekly at 7.5, 8.5, 11.5, 12.5, 23.5, and
28.5 weeks post-conception. She also received 5-
fluorouracil 1,200 mg weekly at 7.5, 8.5, 11.5, 12.5, 15.5,
16.5, 19.5, 20.5, 23.5, and 28.5 weeks post-conception.
She received radiation therapy (to the breast and chest
wall area) from 15.5 weeks through 25 weeks post-
conception. The total fetal radiation dose was estimated
to be 14 rads. MP’s karyotype was normal.
At 81⁄2 years his height was 107 cm (24 S.D.), weight
16 kg (23 to 4 S.D.), and head circumference 47 cms (24
S.D.). He has hypertelorism, a frontal hair whorl, an
upsweep of the frontal hairline, microcephaly, low-set
ears, micrognathia (Fig. 6), and a right palmar simean
crease. The extremities are normal. On Stanford Binet
Intelligence test IV-revised, he earned a composite IQ of
70. This is in the ‘‘mentally deficient’’ to low ‘‘borderline’’
limits of intelligence compared with other students his
age. His speech and language skills are in the mildly
Fig. 1. Case 1 showing hypertelorism, sparse eyebrows, low-set ears,
and prominent nose.
Fig. 2. A: Hands of Case 1 showing excess flexion creases. B:
Radiographs of hands of Case 1 at age 6 years prior to surgery, showing
syndactyly of fingers and hypoplasia of middle phalanges of 2nd and
5th fingers.
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mentally deficient range. He stutters and has verbal
expressive difficulties. He does not show any behavioral
abnormalities and gets along with classmates.
CASE 3
Three-and-a-half-year-old DC was born at 29 weeks
gestation weighing 1,160 g (approximately 50th percen-
tile) to a then 33-year-old gravida 1 para 1 woman of
African-American descent. At 9 weeks post-conception
(i.e., 11 weeks after her last menstrual period) she
underwent dilatation, suction, and curettage in an
attempted elective abortion. Two weeks later, being still
pregnant, she was offered an abortion via a hyster-
otomy. The hysterotomy was recommended because of
the risk of hemorrhage from large uterine myomas.
Instead, she chose to have a medical abortion with
methotrexate. Her methotrexate schedule was 100 mg
bi-weekly from 11 weeks and 5 days to 17 weeks
post-conception and 200 mg bi-weekly from 17 to 23
weeks post-conception. At 34 months of age his weight
was 10 kg (23.5 S.D.), length 87 cm (23 S.D.), and his
head circumference was 51.5 cm (75th percentile). He
has a bulging forehead, bitemporal narrowing, upward
slanting palpebral fissures, sparse hair on the temporal
areas, low-set ears, broad nasal tip, and a high arched
palate. His psychomotor development is normal. The
family did not consent for publication of DC’s photo-
graphs. Chronic diarrhea since the age of 9 months was
Fig. 3. Case 1 showing subluxation of radial heads.
Fig. 4. A,B: Feet of Case 1 with only 4 metacarpals and hypoplasia of toes.
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considered the cause of his poor weight gain. Extensive
investigations for the diarrhea have not led to a specific
diagnosis. An intestinal biopsy initially showed villous
atrophy.
DISCUSSION
Thiersch (’52,’56), Meltzer (’56), and Warkany et al.
(’59) reported fetal malformations associated with ma-
ternal ingestion of aminopterin. Subsequent reports
include those by Milunsky et al. (’68), Shaw and Stein-
bach (’68), Powell and Eckert (’71), Howard and Rudd
(’77), Reich et al. (’78), and Shaw and Rees (’80). Many
children with aminopterin embryopathy died in in-
fancy. There have been no reported cases since 1980.
The risk for malformation is not 100% as shown by the
reports of Freedman et al. (’62) and Pizzuto et al. (’80).
Feldkamp and Carey (’93) reviewed published cases of
fetal aminopterin syndrome and suggested that the
critical period for the development of malformations is
6 through 8 weeks post-conception and the minimum
dose to be 10 mg per week.
Our Case 2 was initially exposed at 71⁄2 weeks at a
much larger dose, but did not develop the digital
anomalies. Similarly, the case reported by Shaw and
Steinbach (’68), who was exposed from 8–9 weeks, and
Howard and Rudd’s (’77) patient exposed at 8 weeks
showed no digital anomalies. Our Case 2 was also
exposed to 5-fluorouracil from 7.5 weeks post-concep-
tion. Experience with 5-fluorouracil during pregnancy
is limited but, following systemic therapy in the first
trimester, Stephens et al. (’80) reported multiple birth
defects in an aborted fetus: radial aplasia, absent
fingers, aplasia of the esophagus and duodenum. Our
patient does not show these anomalies.
Case 3 in this report was exposed at 11 weeks and 5
days and onward, and showed a different and milder
phenotype. This case suggests that the teratogenecity
of methotrexate may extend through 11 weeks post-
Fig. 5. Case 1 with skull defects.
TABLE 1. Comparison of clinical data




Reich et al. (’78) Shaw and
Steinbach
(’68)Case 1 Case 2 Case 3
Aminopterin
exposure 2 ? 1 ? 1
Methotrexate
exposure 1 ? 2 ? 2
Time of exposure
in weeks 6–8 8–12 6–8 ? 8–9
Bitemporal flat-
tening, brachy-
cephaly 1 1 1 1 2
Characteristic
frontal hairline 1 1 1 1 1
Hypoplastic
supraorbital
ridges 2 1 1 1 1
Sparse and faint
eyebrows, lat-
eral half 1 1 1 1 1
Hypertelorism 1 1 1 1 1
Prominent eye-
balls 2 2 1 1 1
Small palpebral
fissures 1 1 1 1 1
Prominent nose 1 1 1 1 1
High arched
palate 1 1 1 1 1
Micrognathia 2 1 1 1 1
Low-set ears or
malformed ears 1 1 1 1 1
Microcephaly 1 2 2 2 1
Distal shortening




elbows 1 1 1 1 1
Subluxation of
radial heads 1 1 1 1 1
Defects in skull
bones 1 1 2 1 1
Brachydactyly/
syndactyly/hy-
poplasia digits 1 1 1 1 2
Abnormal derma-
toglyphics 1 1 1 1 2
Short stature 1 1 1 1 1
Normal intelli-
gence 1 1 1 1 1
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conception but the syndrome then is milder. Methotrex-
ate is useful in the treatment of many types of cancers,
rheumatoid arthritis, and psoriasis. It has been shown
to be safe and effective in medical treatment of ectopic
pregnancy as reviewed by Slaughter and Grimes (’95).
Methotrexate followed by misoprostol has been pro-
posed as a means of terminating very early pregnan-
cies. Failed treatment carries the risk of the fetal
methotrexate syndrome.
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Fig. 6. Case 2 showing hypertelorism, upsweep of frontal hair line,
and micrognathia.
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